SNP Resequencing
Description of Services
- Assay development and validation with many pre-validated genes already available.
- PCR amplification and product purification
- Bi-directional DNA sequencing on ABI 3730xl DNA sequencers
- Mutation profiling & sequence variation reporting
- Geospiza Finch® Suite sample tracking
- Automated calling & manual curation of heterozygotes
- Optional 2 assay-platform packages for strong validation of any SNPs
- ASSAY TESTING AGAINST THE HAP-MAP SAMPLES
- Experienced with tumor sample and working with parrafin-embedded tissues
- dbSNP submission available
2-Platform, Mutation-Validation Assay Packages
For highly reliable confirmation of novel SNPs, it is recommended that a second assay-platform be used to validate the mutation. Following mutation discovery by sequencing, the most common secondary method is a SNP genotyping/allelic discrimination assay. SeqWright offers this 2-assay approach as an integrated package for high-confidence data suitable for any publication.
Assay Testing Against the HapMap Samples
If a new mutation has been discovered in a patient panel, a valuable next step approach is to screen the mutation against the HapMap samples, available from the Coriell Institute, for any positive haplotype associations that may contribute to a particular disease or drug response. The HapMap panels are commercially available. SeqWright will provide consultation about which HapMap panel is most appropriate for a particular study and will screen the set for the new mutation.
Tumor Samples & Heterogeneous Mixtures
SeqWright is experienced detecting low-frequency mutations in uneven mixtures, such as tumor samples and pooled DNA, as low as 10% using standard PCR and sequencing. Mixtures with mutations below 10% can be detected using a subcloning strategy.
Heterozygote insertion-deletions (indels) are detected by the frameshift in data and the loss of signal quality at the boundary. Again, the 10% threshold applies. The deconvoluted hetero-indel peak profiles are included in the final report.
- DNA extraction from paraffin-embedded tissue
- Detection of low-frequency mutations as low as 10% without subcloning
- Detection and deconvolution of hetero-indel profiles
- Whole Genome Amplification (WGA) for low sample quantities
- CLIA certified for handling patient samples
- 21 CFR 58 and 21 CFR 11 compliant
**Not for diagnostic purposes.
DNA Amplification (EBV Transformation and WGA)
Whether limited by very small sample amounts or needing to maintain a perpetual supply of DNA belonging to a specific genotype, SeqWright offers services for both increasing and preserving critical DNA samples for future studies. Methods have been validated for both STR and SNP genotyping.
Additional Resources
|